Macrophage-Based Therapy

Autologous non-polarized human macrophages administered intravenously address the limitations of liver cirrhosis treatments by reducing fibrosis and improving liver function, providing a promising alternative to transplantation.

JP7581049B2Active Publication Date: 2024-11-12THE UNIV COURT OF THE UNIV OF EDINBURGH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2020549605
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-03-16
Filing Date
2019-03-15
Publication Date
2024-11-12
Estimated Expiration
2039-03-15

AI Technical Summary

Technical Problem

Current treatments for liver cirrhosis, such as liver transplantation, are limited by donor organ availability and require lifelong immunosuppression, while alternative therapies to prevent or delay the progression to the decompensated terminal phase are urgently needed.

Method used

Administration of autologous, non-polarized human macrophages derived from monocytes, characterized by high expression of markers like 25F9 and CD206, and administered intravenously to treat liver cirrhosis caused by alcohol, obesity, or viral infections.

Benefits of technology

The treatment reduces fibrosis and promotes liver regeneration, as evidenced by improvements in MELD scores, liver function markers, and reduced fibrosis indicators, offering a viable alternative to transplantation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007581049000012
    Figure 0007581049000012
  • Figure 0007581049000013
    Figure 0007581049000013
  • Figure 0007581049000014
    Figure 0007581049000014
Patent Text Reader

Abstract

The present invention relates to autologous isolated non-polarized human macrophages for use in the treatment of liver disease, and to macrophages for use in a method of treating fibrosis in a human in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Liver cirrhosis is a major health problem in Western countries. In the UK, liver disease is the fifth leading cause of death, with over one million deaths estimated to be the result of cirrhosis in 2010. This disease is associated with high levels of morbidity due to progressive tissue damage, fibrous scarring, and loss of liver function, and liver transplantation is the only treatment option for end-stage disease. However, donor organ availability cannot meet demand, and patients with end-stage liver disease are often ineligible for transplant. Transplant recipients require lifelong immunosuppression, which carries increased health risks. In 2015, 611 patients were reported to be on the UK living donor liver transplant list. Patients may wait up to two years before receiving a liver transplant. One year after registration, 17% of patients were still on the liver transplant list. Similarly, in the US, there are many patients on the liver transplant waiting list (LTWL) for whom a donor organ may not be identified. Approximately 1,700 patients die on the waiting list each year or are removed from the list due to deteriorating health, while approximately 6,500 remain on the list for more than six months. Treatment of end-stage liver disease has become a major concern worldwide. [Background technology]

[0002] Alternative therapies that prevent or delay the progression to end-stage decompensated liver disease are urgently needed.

[0003] The pathology of liver cirrhosis is driven by a number of causative factors, such as high alcohol consumption, obesity, metabolic disorders, viral infections, or autoimmune diseases, and healthy liver tissue and liver architecture are gradually lost and replaced by myofibroblast-derived fibrous scars. It is increasingly recognized that liver fibrosis is at least partially reversible and liver regeneration is possible when factors that promote liver damage, such as alcohol or viruses, are eliminated.

[0004] Animal models of liver regeneration after experimental liver injury have demonstrated that macrophages may play an important role in the control and repair of fibrotic liver disease. Hepatic macrophages are a heterogeneous population of cells, including resident Kupffer cells and recruited hematopoietic-derived macrophages, and have diverse roles in the liver's regenerative response after injury, including phagocytosis, maintaining immune tolerance, hepatic stellate cell activation / cytokine production, and promoting and resolving inflammation and fibrosis via extracellular matrix degradation.

[0005] Several macrophage-directed therapeutic approaches for liver disease have been reported (e.g., as reviewed in Tacke et al., J. Hepatology 2017;66:1300-1312), but they face various challenges due to the complex nature of phage function and interactions in macrophage pathology. Furthermore, macrophage subsets can exert completely opposing functions, suggesting that therapeutic intervention requires careful consideration and establishment of the specific characteristics of administered macrophages, as well as their optimal dosage and timing. Summary of the Invention [Problem to be solved by the invention]

[0006] The administration of non-polarized monocyte-derived mature macrophages in humans and their efficacy in treating liver cirrhosis has not previously been evaluated. [Means for solving the problem]

[0007] Thus, in a first aspect, the present invention provides autologous isolated non-polarized human macrophages for use in the treatment of liver disease.

[0008] In some embodiments, non-polarized human macrophages for use according to any aspect or embodiment of the present invention are derived from monocytes. In some embodiments, non-polarized human macrophages for use according to any aspect or embodiment of the present invention are mature macrophages. Suitably, macrophages for use according to the present invention are characterized by high or elevated expression of at least one macrophage-associated surface marker, such as 25F9 or CD206; in some embodiments, expression is "high" or "elevated" compared to the expression levels of these markers on source cells, such as progenitor cells or freshly isolated peripheral blood monocytes. Other surface markers include the presence and / or elevated expression of one or more of CD163 or CD169. In some embodiments, a lack of CD93 and a decrease in the inflammatory cytokine receptor CCR2 can be detected compared to isolated CD14+ monocytes on day 0. In certain embodiments, the non-polarized macrophages are characterized by positive expression of CD45 / CD14, have a viability of greater than 80%, and have an MFI (mean fluorescence intensity) for surface markers 25F9 and CD206 that is 5-fold or greater than the MFI of the original monocytes on day 0.

[0009] In one embodiment, autologous isolated non-polarized human macrophages for use in accordance with any aspect or embodiment of the present invention are prepared from CD14+ monocytes isolated from the peripheral blood of an affected patient. Suitably, these CD14+ monocytes are incubated with M-CSF for at least 48 hours, or for 3 to 5 days, or for 7 days. In some embodiments, M-CSF is used at a concentration of approximately 100 ng / ml, although it will be understood that this may be varied to obtain non-polarized macrophages with desired characteristics. In one embodiment, non-polarized macrophages for use in accordance with any aspect or embodiment of the present invention are obtained or obtainable by the process described in the Examples herein. In particular, the process is as described in Example 4A or Example 4B herein. In a further aspect, the present invention provides autologous macrophages obtained or obtainable by the process described in Example 4A or Example 4B. In some embodiments, the monocytes are incubated in T cell medium as described herein.

[0010] In some embodiments, the autologous isolated non-polarized human macrophages according to the present invention are for use in liver cirrhosis, preferably cirrhosis caused by either high alcohol consumption, obesity, metabolic disorders or viral infection, most preferably alcohol-induced cirrhosis, NASH or HCV.

[0011] In other embodiments, the autologous isolated non-polarized human macrophages are for intravenous administration. Suitably, the dose is approximately 10 7 From 10 9 cells, suitably at least 10 7 cells, at least 10 8 Or at least 10 9 Multiple doses may be administered.

[0012] In another aspect of the present invention, macrophages are provided for use in a method for treating fibrosis, preferably cirrhosis, by administering one or more doses of the macrophages to a human in need thereof. In one embodiment, one, two, three, or more doses of the macrophages are administered to a human in need thereof, with an interval of approximately one month between each of the doses. In one embodiment, the first dose is administered on day 1, the second dose on day 30, and the third dose on day 60. In one embodiment, the macrophages are comprised in a pharmaceutical composition. In one embodiment, administration of the macrophages results in a reduction of fibrosis.

[0013] In some embodiments, the human in need thereof has cirrhotic liver disease. Suitably, the human is an affected patient with a MELD score of 10-16.

[0014] The number of macrophages in each dose can vary depending on the individual being treated. In some embodiments, each dose contains at least 1 x 10 macrophages per dose. 7 Macrophages, suitably 1 x 10 8 or 1 x 10 9 Contains macrophages.

[0015] In one embodiment, administration of each dose is by intravenous administration. Suitably, the intravenous administration is via a peripheral vein.

[0016] Macrophages for use in the methods according to this aspect of the invention are preferably non-polarized. Suitably, such macrophages are characterized by higher expression of 25F9 or CD206 than that found in the monocytes from which they are derived. In some embodiments, the non-polarized macrophages are derived from a person's own PBMCs, i.e., autologous. In other embodiments, the non-polarized macrophages may be allogeneic, e.g., derived from a healthy donor for administration to a patient with a relevant disease. In other embodiments, the non-polarized macrophages may be derived from stem cells bone marrow (BM), embryonic stem cells (ESCs), or induced pluripotent stem cells (iPSCs). Methods for generating suitable macrophages are described herein.

[0017] In another aspect, the present invention provides a method for administering up to 10 doses of 3-aminobenzamidopropyl benzoate to a human with a MELD score of 10-16. 9 Autologous macrophages are provided for use in a method for treating liver cirrhosis by intravenous administration of cells. Suitably, these doses are provided at approximately monthly intervals or approximately 30-day intervals. In some embodiments, the use of autologous macrophages according to the present invention can be combined with another drug or anti-fibrotic agent used to treat liver cirrhosis. In some embodiments, the other drug may be G-CSF, such as recombinant human G-CSF.

[0018] Other aspects and embodiments of any of the aspects of the present invention are set out in the following numbered paragraphs:

[0019] 1. A method for preparing autologous isolated non-polarized human macrophages, comprising: a) isolating monocytes from the peripheral blood of a patient, suitably a diseased human patient; b) incubating the isolated monocytes in a medium containing 50 to 150 ng / ml of M-CSF for at least 48 hours; A method comprising:

[0020] 2. The method according to item 1, wherein the isolated monocytes are incubated with 100 ng / mL of M-CSF.

[0021] 3. The method according to item 1 or item 2, wherein the isolated monocytes are incubated in a culture bag.

[0022] 4. The method according to any of items 1 to 3, wherein the isolated monocytes are incubated with M-CSF for 7 days.

[0023] 5. Isolated monocytes are cultured at 1 cm 2 per ml and 2 x 10 6 5. The method according to any one of items 1 to 4, wherein the cells are incubated at a density of monocytes.

[0024] 6. The method according to any of items 1 to 5, wherein the monocytes are characterized by surface expression of CD14.

[0025] 7. The method according to any of items 1 to 6, wherein monocytes are isolated using CD14 microbead selection.

[0026] 8. The method according to any of items 1 to 7, wherein after incubation with M-CSF, the autologous isolated non-polarized human macrophages are characterized by positive expression of CD45 / CD14, have a viability of more than 80%, and have an MFI (mean fluorescence intensity) for the surface markers 25F9 and CD206 that is more than 5-fold higher than the MFI of the original monocytes on day 0.

[0027] 9. The method according to any of items 1 to 8, wherein the affected patient has cirrhosis.

[0028] 10. The method according to item 9, wherein the cirrhosis is caused by either high alcohol consumption, obesity, metabolic disorders or viral infections.

[0029] 11. A preparation of autologous non-polarized human macrophages for administration to an affected patient, comprising: a) non-polarized human macrophages produced according to any of the methods of items 1 to 10; b) excipients and Including, c) the non-polarized human macrophages exhibit high expression of at least one surface marker selected from 25F9, CD206, CD163, CD169 or a combination thereof, and / or d) The formulation contains at least 1 × 10 7 and / or e) the product is formulated as an infusion solution for intravenous or subcutaneous administration; and / or f) the formulation contains less than 4.5% v / v serum; formulation.

[0030] 12. The formulation according to item 11, wherein the excipient comprises 0.9% v / v saline with 0.5% v / v human serum albumin.

[0031] 13. A method for treating liver disease in humans by administration of autologous isolated non-polarized human macrophages.

[0032] 14. The method according to item 13, wherein the non-polarized human macrophages are derived from monocytes.

[0033] 15. The method according to any of items 13 to 14, wherein the non-polarized human macrophages have increased expression of 25F9 or CD206 compared to the source cells.

[0034] 16. The method according to any of items 13 to 15, wherein non-polarized human macrophages are prepared according to the method according to any of items 1 to 10.

[0035] 17. The method according to any of items 13 to 16, wherein the administration is preferably by intravenous injection.

[0036] 18. The method according to item 17, wherein the injection is via a peripheral vein.

[0037] 19. Administration or injection is 10 7 ~10 9 18. The method according to any of items 13 to 17, wherein the dose is intracellular.

[0038] 20. The method according to item 19, in which the patient receives three injections spaced one month apart.

[0039] 21. The method according to any of items 13 to 19, wherein the patient has a MELD score of 10 to 16.

[0040] 22. A method for treating liver disease in a patient with a MELD score of 10 to 16, comprising administering therapeutically effective amounts of a) autologous macrophages prepared according to the method described in any one of items 1 to 10, and b) an anti-fibrotic agent and / or G-CSF.

[0041] 23. A method for promoting hepatocyte regeneration in the liver, comprising administering to a patient an effective amount of autologous isolated non-polarized human macrophages.

[0042] 24. The method according to item 23, wherein the administration is intravenous, preferably via a peripheral vein.

[0043] 25. The method according to item 23 or item 24, wherein the patient has alcohol-induced cirrhosis.

[0044] 26. 10 per dose 7 From 10 9 26. The method of any of items 23 to 25, wherein autologous cells of [Brief explanation of the drawings]

[0045] [Figure 1]Initial optimization of GMP macrophage cultures from normal donors. A) CliniMACS CD14 bead isolation of monocytes using an LS column generated a highly purified CD14 fraction (n=26). B) CliniMACS Prodigy CD14 selection produced a similarly highly enriched CD14+ fraction from apheresis samples from cirrhotic volunteers. C) Cirrhotic patients showed a trend toward higher CD14 counts in peripheral blood (n=11, p=0.108). D) Although not significant, TexMACS resulted in the highest and most consistent macrophage yield (n=6-10). E) Macrophages from TexMACS cultures were significantly larger in size than those cultured in AIM-V medium (p<0.0001, n=5). F) GMP-grade M-CSF from R&D produced similar macrophage yields as standard M-CSF, but with stronger expression of the macrophage marker 25F9 (n=6). G) Microscopic images show that DMEM + 5% AB produced aggregation and adherence in macrophage cultures, unlike those produced in defined media. (Fraser et al., Cytotherapy 2017;19(9):1113-1124) [Figure 2] This graph shows the phenotype of fresh and frozen monocytes from GMP macrophages. Buffy coat monocytes were isolated, an aliquot frozen, and stored in LN2, while the remainder was used to generate macrophages. After thawing, the monocytes were cultured to generate macrophages, and the phenotypes were compared. While most markers remained unchanged in macrophages generated from thawed monocytes, CD206 and CD163 were significantly decreased, and CCR2 was significantly increased in macrophages generated from frozen monocytes (n = 10). [Figure 3] Phagocytosis of monocytes and macrophages. (A) Bright field / fluorescein isothiocyanate fluorescence EVOS images (magnification ×100) showing uptake of pHRodo beads. (B) Quantification of uptake shows no significant difference in bead uptake by monocytes or macrophages, and no difference in the number of beads ingested (n = 4). Data are expressed as mean ± SD. [Figure 4]Microscopic and phenotypic changes in polarized macrophages. A) EVOS brightfield images (magnification x400) of polarized macrophages showing clear differences in morphology between angular, pointed M1 / M (IFNg) and elongated, smooth, spindle-shaped M2 / M (IL-4) macrophages. B) Flow cytometry analysis shows no significant differences in macrophage marker 25F9, but IL-4 stimulated macrophages significantly increased CD206 expression, whereas IFN-g treated macrophages decreased it (n=5, mean + / - sd, p<0.05). [Figure 5] Figure 1 shows secretome analysis of macrophages from healthy donors. Day 7 macrophages (n=3) were untreated or stimulated with TNF-α and poly I:C (PIC) or IFNg and LPS for 12 hours and analyzed by BioRad multiplex ELISA. Both IL-10 (A) and IL-1Ra (B) were significantly upregulated by TNF-α / PIC, as was VEGF (D). IL-12p40 levels (C) were unaffected by TNF-α / PIC but significantly increased by LPS / IFNg. Data are presented as mean + sd, *p<0.05. [Figure 6] Graphs depict a phenotypic panel (n=7) of clinical-grade macrophages collected from patients with cirrhosis. A) Release criteria showing increased MFI between day 0 monocytes and day 7 macrophages. B) Expanded panel including two additional scavenger receptors (CD163 / CD169) and markers of macrophage migration. Note that there was one outlier in the day 7 data for CCR2, which was removed from analysis after Grubb's test (●). Data are expressed as mean + / -, p<0.05. [Figure 7]Graphs showing the stability of macrophages from GMP cirrhosis patients. A) Viability shows no significant decline even after 48 hours at room temperature. B) 25F9 expression steadily decreases over time, but even at 48 hours remains well above the 5-fold increase required for efficacy. C) CD206 remains high until approximately 24-30 hours after collection, then declines more rapidly, but still remains well above the 5-fold threshold established by the study criteria (n=3). [Figure 8-1] Figure 8. Genetic changes in apheresis-derived monocytes on day 0 and after differentiation on day 7 in healthy volunteers (n=5) and patients with liver cirrhosis (n=8) (ns, not significant; *P<0.05, mean and SEM). (Moore JK et al., Cytotherapy. 2015; 17(11):1604-16). [Figure 8-2] Continued from Figure 8. [Figure 9] Graph showing the mean ΔMELD for all patients in the MATCH study. d360 data for patients 9, 10, and 11 are not included. [Figure 10] Graph showing mean ΔMELD for MATCH patients and the contribution of three components: BIL, CRE, and INR. d360 data for patients 9, 10, and 11 are not included. [Figure 11] Graph showing the ELF scores for all patients in the MATCH study. [Figure 12] 1 is a graph showing the ΔELF of all patients in the MATCH study. [Figure 13] 1 is a graph showing HA levels for all patients in the MATCH study. [Figure 14] 1 is a graph showing PNIIIP values ​​for all patients in the MATCH study. [Figure 15] Graph showing TIMP1 levels for all patients in the MATCH study. DETAILED DESCRIPTION OF THE INVENTION

[0046] macrophages Macrophages are phagocytes of two distinct origins: tissue-resident macrophages, derived from fetal cells and distributed throughout all tissues in the body, and peripheral blood monocyte-derived macrophages, which can differentiate in response to signals such as injury, inflammation, and disease. Monocyte-derived macrophages have a wide range of context-dependent functions, participating in the control of infectious organisms, removal of damaged cells, and tissue repair. The earlier classification of macrophages into M1 (classically activated, pro-inflammatory) and M2 (alternatively activated, anti-inflammatory) states is considered an oversimplification; macrophages can have both pro- and pro-inflammatory functions, depending on the activation method and cytokine environment, as described, for example, by Murray et al. (Immunity 2014; 41:14-20) and Tacke et al. (J. Hepatology 2017; 66:1300-1312).

[0047] In the liver, macrophages can promote fibrogenesis by activating the profibrotic cytokine transforming growth factor (TGF)-β and by stimulating myofibroblast proliferation via platelet-derived growth factor (PDGF), IL-1β, and tumor necrosis factor-α. They are also important for the resolution of fibrosis because they provide a rich source of scar-degrading matrix metalloproteinases (MMPs). They produce factors such as MMP-9, which promote hepatic stellate cell apoptosis, necessary for scar resolution. They also phagocytose cellular debris and eliminate potential proinflammatory signals. The wide variety of responses is reviewed, for example, by Tacke et al. (J. Hepatology 2017; 66:1300–1312).

[0048] Cirrhotic donors typically have high numbers of circulating monocytes, typically >30% of total nucleated cells (TNC), significantly higher than reported values ​​from healthy donors or CD14-treated patients (Campbell et al., Methods Mol Med. 2005;109:55-70), which correlates closely with disease progression (Zimmermann et al., PLoS One 2010;5(6):e11049). However, it has not previously been established that monocytes isolated from cirrhotic patients can differentiate into functional macrophages comparable to those from healthy volunteers. The data presented herein report no significant differences in the function of macrophages derived from cirrhotic patients and healthy volunteers, indicating that ex vivo maturation of circulating monocytes may be a technique for generating therapeutic mature macrophages for clinical cell therapy. Therefore, the use of autologous cells, i.e., the cirrhotic patient's own cells, is advantageously provided, minimizing the risk of bioincompatibility and immune reactions associated with cell therapy. Furthermore, a very high initial number of target cells may reduce the overall selection efficiency due to excessive reagent and selection column volumes. Despite the high monocyte numbers in cirrhotic patients, the CliniMACS Prodigy system was surprisingly able to reproducibly isolate enough cells to meet the manufacturing standard of at least 40% CD14+ cell yield.

[0049] As described herein, monocytes are cultured in a GMP-compliant, antibiotic-free defined medium, producing a macrophage conversion rate of approximately 45%. Culture conditions differ from previous prior art.

[0050] Non-polarized macrophages Suitably, a "non-polarized macrophage" according to the present invention is a mature macrophage (i.e., fully differentiated from a source macrophage precursor or progenitor cell such as a monocyte), but is not polarized (i.e., has not received further stimuli that induce a specific functional capability). Non-polarized macrophages may also be described as "naive" or "non-activated."

[0051] In one embodiment of any aspect of the invention, the non-polarized macrophages are monocyte-derived cells. Thus, the non-polarized macrophages may be derived, for example, by leukapheresis or from peripheral blood mononuclear cells (PBMCs) removed from a blood sample and by isolating and culturing the mononuclear cells. Suitably, the monocytic cells are CD14+ cells, which can be isolated by selecting for CD14 expression. Suitable methods are described herein and may include magnetic microbead selection.

[0052] In some embodiments, PBMCs are removed from a patient to be treated to obtain patient-derived monocytes capable of generating autologous non-polarized macrophages. Suitable methods for removing PBMCs from a patient are described, for example, herein. The advantageous use of autologous cells avoids problems encountered with non-autologous approaches, such as the introduction of exogenous bacteria or viruses, bioincompatibility, and immune rejection. In other embodiments, the non-polarized macrophages can be allogeneic, i.e., derived from monocytes obtained from a healthy donor. Suitably, the healthy donor is matched, e.g., HLA type-matched. Briefly, a method for generating non-polarized macrophages involves culturing CD14+ monocytes isolated from PBMCs in the presence of M-CSF to generate mature macrophages. Suitably, the isolated monocytes may be incubated for at least 48 hours or longer, e.g., 3 days or longer, preferably 7 days. In some embodiments, patient-derived PBMCs may be maintained for a period of time, e.g., overnight, before processing or culturing to generate mature non-polarized macrophages. In some embodiments, the isolated cells may be provided in a culture bag.

[0053] In some embodiments, non-polarized macrophages are generated from patient-derived monocytes according to the culture methods and conditions described in the Examples section herein. In some embodiments, the culture medium is any medium suitable for generating these non-polarized macrophages from source cells. The medium may be serum-free. Suitably, the medium is a chemically defined medium, such as a Good Manufacturing Practice (GMP) defined medium supplemented with an appropriate concentration of M-CSF. In some embodiments, the M-CSF may be recombinant M-CSF, preferably recombinant human M-CSF. Advantageously and surprisingly, the medium is not specifically optimized for macrophage culture, but is instead optimized for the culture and expansion of T cells. In one embodiment, the medium is TexMAC (Miltenyi) or AIM-V (Thermofisher).

[0054] Suitably, the concentration of M-CSF is 50-150 ng / ml, e.g., 100 ng / ml. In some embodiments, the method for preparing autologous non-polarized macrophages generates a population of non-polarized macrophages with a viability of greater than 80%, which may be measured by methods well known to those skilled in the art, such as DRAQ7 staining as described herein.

[0055] Suitably, non-polarized mature macrophages are characterized by elevated expression of at least one or both of the surface markers "25F9" and CD206. "Elevated" expression refers to increased expression compared to the expression of these markers in source macrophage precursor or progenitor cells, such as monocytes (e.g., isolated day 0 / naive monocytes). In some embodiments, "elevated" expression refers to expression of a surface marker that is at least approximately five-fold higher compared to the source cells. Marker expression can be determined by methods known to those skilled in the art, including fluorescent labeling techniques as described herein. Suitably, levels or expression may be measured by mean fluorescence intensity (MFI) using the methods described herein. 25F9 refers to a macrophage marker antibody provided by eBioscience / Thermofisher that recognizes a marker on mature macrophages, but not immature macrophages or monocytes, or other blood cells. The marker to which the antibody binds is unknown; the name is derived from the antibody clone. More details are provided here (https: / / www.thermofisher.com / antibody / product / Mature-Macrophage-Marker-Antibody-clone-eBio25F9-25F9-Monoclonal / 50-0115-41). In some embodiments, a label, such as an antibody that competes with 25F9 for binding to the same surface marker, may also be used to identify a non-polarized macrophage phenotype. As used herein, "expression of 25F9" refers to the expression of a marker to which 25F9 binds.

[0056] In some embodiments, the source monocytes are CD45 + , CD14 + , 25F9 - , CD206 - Incubation in an appropriate medium, such as medium containing M-CSF, induces the expression of CD45 + , CD14 + , 25F9 + , CD206 +In a further embodiment, these source monocytes also express CCR2 high , CD163 low , CD169 low characterized by CCR2 mid , CD163 + , CD169 + They mature into non-polarized macrophages characterized by

[0057] Other markers that may be increased in expression on "non-polarized macrophages" include increased levels of CD163 and CD169 and decreased levels of CCR2. In some embodiments, non-polarized macrophages may be described as anti-inflammatory and / or anti-fibrotic due to the expression of specific surface markers or scavenger receptors involved in the clearance and uptake of damaged cells, fibrotic material, and pro-inflammatory cytokines. Macrophage nomenclature is reviewed, for example, in Martinez and Gordon (F1000Prime Rep. 2014;6:13).

[0058] In some embodiments, non-polarized mature macrophages may be polarized to an M1 or M2-like phenotype by incubation with appropriate polarization factors; for example, M1 polarization may be obtained by incubation with INF-gamma or TLR agonists such as LPS or poly(I:C), while M2 polarization may be obtained by stimulation with IL4.

[0059] Non-polarized mature macrophages can be derived from stem cells such as embryonic stem cells (ES cells), human induced pluripotent stem cells (human iPSCs), and bone marrow-derived hematopoietic stem cells.

[0060] Various methods for producing macrophages from pluripotent stem cells, such as ES cells and iPSCs, are known in the art; see, for example, van Wilgenburg et al. (PLoS One 2013; 8(8):e71098). Methods for determining that the developed cell line is pluripotent and has a normal karyotype are described, for example, in Yang et al. (Stem Cells 2017; 35(4):886-897). Suitable human induced pluripotent stem cell lines include, for example, SFCi55, which is described in co-pending application PCT / GB2017 / 052769.

[0061] A suitable method for generating macrophage progenitors from such human iPS cell lines is as follows: iPSCs were maintained in StemPro medium prepared by supplementing DMEM / F12 with Glutamax (Invitrogen) with StemPro supplement (Invitrogen), 1.8% BSA (Invitrogen), 0.1 mM β-mercaptoethanol (Invitrogen), and 20 ng / ml human basic FGF (Invitrogen). Methods for differentiating iPSCs into macrophages are described in van Wilgenburg et al. On day 0, spent medium was removed from one confluent well of a 6-well plate and replaced with 2 ml of StemPro (ThermoFisher) supplemented with cytokine mix 1 (50 ng / ml BMP4, 50 ng / ml VEGF, and 20 ng / ml SCF). Cells were dissected using an EZPassage™ tool and gently removed with a Pasteur pipette. They were divided equally into two wells of an ultra-low attachment 6-well plate (Corning), and 2 ml of X-VIVO™ 15 medium containing Cytokine Mix 1 was added to each well. The cells were cultured in suspension for 3 days (cytokines were supplemented on day 2) to generate embryoid bodies (EBs). On day 4, EBs were lifted and transferred to gelatin-coated tissue culture-grade 6-well plates in X-VIVO™ 15 medium supplemented with Cytokine Mix 2 (100 ng / ml M-CSF, 25 ng / ml IL3, 2 mM Glutamax, 1% penicillin / streptomycin, 0.055 M β-mercaptoethanol). Approximately 30 EBs were plated per well. EBs were maintained in this medium for the remainder of the protocol, with spent medium replaced with fresh medium every 3–4 days. After approximately two weeks, EBs generated macrophage progenitor cells in the culture supernatant. These were collected and transferred to 10 cm bacteriological dishes in X-VIVO™ 15 medium supplemented with Cytokine Mix 3 (100 ng / ml M-CSF, 2 mM Glutamax, 1% penicillin / streptomycin). They were allowed to mature into iPSC-derived macrophages (iPSC-DMs) over 5–7 days. Macrophage progenitor cells were collected twice weekly for approximately two months.

[0062] Other methods for generating macrophage progenitor cells are described in Yeung et al., Sci. Rep. 2015;5:8908; Zhuang et al., J Immunol Methods. 2012;385(1-2):1-14; Sneju et al., Oncoimmunology 2014;3(1):e27927; Hale et al., PLoS One 2015;10(5):e0124307; Zhang et al., Circ Res. 2015;117(1):17-28; Mucci et al., Stem Cell Reports 2016;7(2):292-305; and van Wilgenburg et al., PLoS One 2013;8(8):e71098.

[0063] Embryonic stem cell-derived macrophages (ESDMs) can be generated by culturing ES cells in the presence of colony-stimulating factor-1 (CSF-1) (also known as M-CSF) and IL-3 to form embryoid bodies (EBs). The EBs adhere to tissue culture plastic, whereas the macrophage precursor cells are nonadherent and are released into the medium. The macrophage precursor cells can then be harvested at various time points, e.g., after 10 or 20 days, plated onto untreated Petri dishes, and cultured in the presence of CSF-1 alone. This process can give rise to monocyte-like cells that adhere to the plastic forming a monolayer and mature into ESDMs.

[0064] Maturation of ES cells into ESDMs can be monitored by detecting the presence of mature macrophage-specific markers, including 25F9 (human macrophage-specific) and / or CD11b. Furthermore, human macrophages may be characterized by the absence of the monocyte marker CD93. Advantageously, the described methods result in a substantially homogenous population of ESDMs.

[0065] Liver disease In some aspects or embodiments, the present invention provides treatment for liver disease in patients, particularly those suffering from liver damage that results in liver fibrosis or cirrhosis. Chronic liver damage leads to scar deposition and loss of hepatocytes. Excessive accumulation of scar tissue leads to liver fibrosis. At this stage, progression of fibrosis can be halted. However, untreated fibrosis can ultimately lead to cirrhosis. In some embodiments, the liver disease is one in which cirrhosis is caused by damage to hepatocytes, such as diseases of viral origin (including treated (sustained viral response) hepatitis C (HCV) and hepatitis B), damage due to alcoholism (alcohol-related liver disease (ALD)), or diseases of hepatocyte origin, such as nonalcoholic steatohepatitis (NASH) (including NASH due to diabetes or obesity), idiopathic cirrhosis, nonalcoholic fatty liver disease (NAFLD), including hemochromocytosis or alpha-1-antitrypsin deficiency. In some embodiments, the underlying etiology has been eliminated (e.g., a patient suffering from damage due to alcoholism no longer drinks, or a patient suffering from damage due to HCV no longer has HCV, etc.).

[0066] Affected patients suitable for treatment or use according to any aspect or embodiment of the present invention may be patients with the relevant disease and severity.

[0067] treatment As used herein, the term "treatment" refers to an intervention that reduces fibrosis in a subject, prevents progression, or partially or completely alleviates clinical symptoms associated with liver disease or injury. Suitably, treatment may result in increased or accelerated liver regeneration. Advantageously, macrophages used in accordance with the present invention provide anti-fibrotic and pro-regenerative cells.

[0068] Suitably, administration of non-polarized human macrophages in accordance with the present invention may result in one or more of the following beneficial effects: reduced fibrosis or reduced liver disease in a subject, reduced necrosis, increased hepatocyte proliferation, reduced levels of pro-inflammatory cytokines, increased phagocytosis at sites of fibrosis.

[0069] Liver disease is typically measured by the MELD (Measure of End-stage Liver Disease) score, a scoring system derived from serum markers blood bilirubin, creatinine, and coagulation. This scale was originally developed to predict mortality and is used to prioritize patients for liver transplantation. It predicts 3-month and 1-year mortality and predicts clinical decompensation in patients with compensated cirrhosis.

[0070] Changes in MELD are a more important determinant of death than initial MELD alone. For any given MELD, the magnitude and direction of change in MELD score over the previous 30 days are significant independent predictors of mortality. The MELD score is used by all major Western regulatory agencies involved in liver transplantation (UK Transplant, Eurotransplant, UNOS) to help prioritize liver transplant allocation. In some embodiments, treatment with nonpolarized human macrophages according to the present invention can result in a change in MELD in a subject. In other embodiments, treatment can result in a change in one of the liver-related components of the MELD score, i.e., bilirubin (BIL) and / or international normalized ratio (INR).

[0071] In other embodiments, treatment with non-polarized human macrophages according to the present invention may result in a change in UKELD. Other methods for measuring efficacy in a subject include assessing changes in liver fibrosis measured by transient elastography, using the Enhanced Liver Fibrosis Test-ELISA, measuring liver metabolic and regenerative activity using labeled metabolites and liver MRI scans, or measuring liver volume and blood flow using MRI. In other embodiments, treatment with non-polarized human macrophages according to the present invention may result in a change in ELF or one of the liver-related components of the ELF score, namely, hyaluronic acid (HA), tissue inhibitor of metalloproteinase-1 (TIMP-1), and propeptide of type III procollagen (PIIINP). In other embodiments, disease-specific biomarkers and epitopes, such as neoepitopes, may be measured. For example, treatment with nonpolarized human macrophages according to the present invention can result in changes in the precisely cleaved N-terminal propeptide of type III collagen (PRO-C3) and / or the peptide of helical collagen type III degradation (C3M). During fibril assembly, the N-terminal propeptide of type III collagen is cleaved by the N-protease, but because removal of the propeptide can be incomplete, PIIINP can be a marker of both fibril formation and degradation, while PRO-C3 is a marker of formation because PRO-C3 is specific for the N-protease cleavage site. For example, ELF, liver-related components of ELF, PRO-C3 and C3M may be measured according to any of the following publications: Thiele et al. (Gastroenterology 2018; 154: 1369-1379), Irvine K et al. (Liver International 2016, 370-377 ISSN 1478-3223), Barascuk N et al. (Clinical Biochemistry 34 (2010) 899-904), and Nielsen MJ et al. (Am J Transl Res 2013; 5 (3): 303-315).

[0072] The term "subject" as used herein refers to any individual who may benefit from treatment of liver damage. The subject may be a human subject, a person in need of treatment, such as an affected patient. Suitably, a person suitable for treatment according to the present invention is one with cirrhotic liver disease, preferably a patient with a MELD score between 10 and 16. A person with liver disease may also be suitable for treatment, such as a person / patient with portal hypertension.

[0073] dose It will be understood that a therapeutically effective amount or dose of non-polarized macrophages will depend on various factors, including the body weight of the subject being treated. By way of example, a therapeutically effective amount may be 1×10 7 From 1×10 9 In some embodiments, the dose may be in the form of a dose of 10 non-polarized macrophages. 7 , 10 8 or 10 9 Suitably, the treatment consists of three doses administered monthly as an infusion, i.e., approximately 10 times the number of macrophages administered approximately 30 days apart. 9 The treatment consists of three infusions of macrophages up to 100 mg / kg. Advantageously, additional doses may allow further degradation of scar tissue to occur. In one embodiment, all doses of macrophages administered to a patient will be collected in a single leukapheresis collection. In some embodiments, the final dose administered may depend on the starting number of monocytes, and may range from 10 to 100 mg / kg, depending on the patient. 8 can be a multiple of .

[0074] In some embodiments, macrophages according to the present invention may be provided in a suitable storage or transport bag.

[0075] Administration The macrophage product according to any aspect of the present invention can be administered to the recipient's body by any suitable means, including, but not limited to, subcutaneous, intramuscular, parenteral, enteral, intravenous, intraperitoneal, intraorbital, intraretinal, by tissue implantation, and into the cerebrospinal fluid. Advantageously, the macrophage product is administered intravenously, such as by intravenous injection or infusion.

[0076] Previous studies have shown that portal vein delivery maximizes the number of cells delivered to the liver, but repeated portal vein administration in patients with cirrhosis carries the risk of portal hypertension and coagulopathy, making this delivery route undesirable in clinical settings. The present inventors have found that this delivery route is clinically effective, although it is likely that fewer cells are distributed to the liver after intravenous injection.

[0077] In some embodiments, non-polarized macrophages for use in accordance with the present invention are prepared in a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be any substance that allows for delivery of the non-polarized macrophages to a subject and may include any suitable diluent or excipient, or combinations thereof. In some embodiments, the non-polarized macrophages may be delivered in saline supplemented with a human albumin solution.

[0078] Thus, non-polarized macrophages for use in accordance with the present invention may be provided in a pharmaceutical composition comprising a therapeutically effective amount of non-polarized macrophages and a pharmaceutically acceptable carrier.

[0079] In suitable embodiments, the pharmaceutical compositions of the present invention may further comprise pharmaceutically acceptable concentrations of salts, buffers, and compatible carriers. The compositions may also include antioxidants and / or preservatives. In some embodiments, the pharmaceutical compositions may include DMSO, for example, 5-10% DMSO.

[0080] combination In some embodiments, macrophage therapy according to the present invention can be combined with another treatment for liver disease. Suitable treatments include treatment with G-CSF. In some embodiments, the other treatment can include antifibrotic drug therapy. Suitable antifibrotic drugs are reviewed, for example, by Wang et al. (Front Physiol. 2016; 7:47; doi:10.3389 / fphys.2016.00047) and Tacke et al. (J. Hepatology 2017; 66:1300-1312).

[0081] Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure.

[0082] All documents mentioned in this specification are incorporated herein by reference in their entirety.

[0083] As used herein, "and / or" should be interpreted as a specific disclosure of each of the two specified features or components, whether or not the other is present. For example, "A and / or B" should be interpreted as a specific disclosure of (i) A, (ii) B, and (iii) each of A and B, as if each were independently set forth herein.

[0084] Unless the context dictates otherwise, the above feature descriptions and definitions are not limited to any particular aspect or embodiment of the invention, but apply equally to all aspects and embodiments described. [Example]

[0085] Certain aspects and embodiments of the present invention will now be described, by way of example, and with reference to the above-mentioned figures.

[0086] Example 1 Optimization of GMP-compliant culture of monocytes Isolation of cells from healthy donors Donor buffy coats, as a source of healthy donor monocytes, were provided by the Scottish National Blood Transfusion Service (SNBTS) Blood Donor Centre in Edinburgh, UK, under SNBTS sample governance guidelines 13-12 and 14-02. CD14 selection from PBMCs: PBMCs were isolated from normal donor buffy coats by density centrifugation using Histopaque 1077 (Sigma). After washing, CD14+ monocytes were isolated from the mononuclear cell fraction using CliniMACS GMP-grade CD14 microbeads and an LS separation magnetic column (Miltenyi Biotec). Briefly, cells were resuspended to the appropriate concentration in PEA buffer (phosphate-buffered saline [PBS] plus 2.5 mmol / L ethylenediaminetetraacetic acid [EDTA] and human serum albumin [0.5% final volume of Alburex 20%, Octopharma]) and incubated with CliniMACS CD14 beads according to the manufacturer's instructions, then washed and passed through a magnetized LS column. After washing, purified monocytes were eluted from the demagnetized column, washed, and resuspended in the relevant medium for culture.

[0087] Isolation of cells from patients with liver cirrhosis For optimization and validation of a full-scale GMP process, peripheral blood mononuclear cells (PBMCs) were collected by leukapheresis at the SNBTS Clinical Apheresis Unit, Edinburgh Royal Infirmary. Ethical approval was obtained from the South East Scotland Research Ethics Committee 02. Informed consent for apheresis transfusion was obtained in accordance with the Declaration of Helsinki. Isolation of CD14+ cells from leukapheresis: PBMCs were collected by leukapheresis from cirrhotic donors who provided informed consent to participate in the study. Eligibility criteria were an age range of 18 to 75 years, and cirrhosis was defined by one of the following: a previous liver biopsy with confirmed histological features of cirrhosis, a transient elastography (Fibroscan) >18 kPa, and / or clinical and radiological features that correlated with a diagnosis of cirrhosis in the opinion of the clinical director. For study purposes, exclusion criteria included conditions requiring ongoing antiviral treatment, such as viral hepatitis, average alcohol intake >21 units / week (men) or >14 units / week (women), ascites not adequately controlled with diuretic therapy in the past 3 months, encephalopathy requiring hospitalization for treatment in the past 3 months, portal hypertensive bleeding in the past 3 months, hepatocellular carcinoma, other cancers within the past 5 years, previous liver transplant or current waitlist status, and the presence of clinically relevant acute illnesses that could compromise safe fetal presentation and pregnancy and / or breastfeeding. Peripheral blood leukapheresis for mononuclear cells (MNCs) was performed by sterile collection using the Optia apheresis system. A standard collection program for MNCs was used, processing 2.5 blood volumes. CD14 cell isolation was performed using a GMP-compliant, functionally closed system (CliniMACS Prodigy system, Miltenyi Biotec). Briefly, the leukapheresis product was sampled for cell counting, and an aliquot was taken for pre-isolation flow cytometry. The percentage of monocytes (CD14+) and absolute cell counts were determined, and the volume was adjusted, if necessary, to meet the required criteria for selection (≤20 × 10). 9 Total white blood cells: <400 × 10 6 White blood cells / mL; ≦3.5×10 9CD14 cells, 50-300 mL volume). CD14 cell isolation and separation were performed using a CliniMACS Prodigy (medical device class III) with CliniMACS CD14 microbeads, a TS510 tubing set, and the LP-14 program. At the end of the process, selected CD14+ positive monocytes were washed with PBS / EDTA buffer (CliniMACS buffer, Miltenyi) containing pharmaceutical-grade 0.5% human albumin (Alburex) and resuspended in TexMACS (or control) medium for culture.

[0088] Cell counting Cell counts of total MNC and isolated monocyte fractions were performed using a Sysmex XP-300 automated analyzer (Sysmex). Because the Sysmex consistently underestimated macrophage numbers, macrophage counts were assessed by flow cytometry using TruCount tubes (Becton Dickinson) to determine absolute cell numbers. Purity of the isolation was assessed using a panel of antibodies against human leukocytes (CD45-VioBlue, CD15-FITC, CD14-PE, CD16-APC) using flow cytometry (FACSCanto II, BD Biosciences). Product quality was assessed by determining the amount of neutrophil contamination (CD45int, CD15pos).

[0089] Cell collection For macrophages from normal donors, cells were removed from the wells on day 7 using Cell Dissociation buffer (Gibco, Thermo Fisher Scientific) and Pastet. Cells were resuspended in PEA buffer, counted, and approximately 10 cells per experiment were collected for flow cytometry. 6Leukapheresis-derived macrophages were removed from the culture bags on day 7 using PBS / EDTA buffer (CliniMACS buffer, Miltenyi) containing 0.5% pharmaceutical-grade human albumin (HAS; Alburex) from serum. Collected cells were resuspended in a vehicle consisting of two licensed products: 0.5% human albumin (Alburex) containing 0.9% saline for injection (Baxter).

[0090] Cell sorting efficiency Sorting efficiency using CD14 CliniMACS beads was very high, and results were comparable across all methods, regardless of whether cells were sourced from buffy coats or leukapheresis from cirrhotic patients; bead-labeled cells were manually labeled and isolated on an LS column, or processed using the fully automated CliniMACS prodigy system. Flow cytometry analysis of presorting and positive and negative fractions demonstrated a high enrichment of the positive fraction (95.9%) from an initial mean of 20.5% monocytes across 26 different normal donor isolations using CliniMACS CD14 reagent and an LS column, with minimal loss of the negative fraction (4.1%) (Figure 1A). Very similar figures were seen in cirrhotic donor samples isolated using the CliniMACS Prodigy (Figure 1B), although cirrhotic donors had a higher (although not significantly higher) initial mean percentage of monocytes within the collection (Figure 1C).

[0091] Optimal medium for culturing monocytes from healthy donor samples We investigated the optimal culture medium for macrophage differentiation and tested three candidates using buffy coat monocytes: Dulbecco's Modified Eagle's Medium (DMEM; Life Technologies) supplemented with 5% AB serum (SNBTS) and two chemically defined serum-free culture media, AIM-V (Thermo Fisher) and TexMACS (Miltenyi). TexMACs medium is an optimized serum-free cell culture medium optimized for the culture and expansion of human and mouse T cells and regulatory T cells, containing preselected human serum albumin, stabilized glutamine, and phenol red (not present in the clinical version). Experiments were performed using buffy coat monocytes cultured at 37°C in a humidified atmosphere with 5% CO2 for 7 days with 100 ng / mL of premium-grade macrophage colony-stimulating factor (M-CSF; Miltenyi) per medium. Cells were seeded into 6-well tissue culture plates at a density of 1.8 x 107 cells / well in 4 mL of medium and refed on days 3–4. Macrophage production in AIM-V complete culture medium has been previously reported (Moore JK et al., Cytotherapy. 2015;17(11):1604-16). However, the antibiotic content of this medium was incompatible with testing product sterility by assessing bacterial growth, so antibiotic-free TexMACS complete medium was evaluated as a comparison medium. GMP-grade TexMACS culture medium consistently resulted in higher macrophage conversion rates compared to AIM-V, although this did not reach statistical significance (Figure 1D). Culture in DMEM plus 5% AB serum also resulted in comparable macrophage conversion rates, although DMEM-cultured macrophages also adhered strongly to the substrate, resulting in cell loss during collection (Figure 1G). Furthermore, monocytes cultured in TexMACS generated significantly larger macrophages, as calculated using forward scatter from flow cytometry (Figure 1E). In early development experiments, we supplemented the culture medium with previously used premium research-grade M-CSF (Miltenyi) (Moore JK et al., Cytotherapy. 2015;17(11):1604-16).This was compared with GMP-grade M-CSF (R&D Systems), both at 100 ng / ml. While there were no significant differences in morphology or macrophage yield between cultures using either source, macrophages generated with GMP-grade M-CSF showed higher expression of the macrophage marker 25F9 (Figure 1F). TexMACS medium (Miltenyi) supplemented with GMP-grade M-CSF (R&D Systems) appears to be the optimal medium for producing GMP-grade macrophages.

[0092] Induction of macrophages from frozen monocytes We also compared macrophage induction from fresh and frozen / thawed monocytes (see the Results section). Monocytes were isolated from buffy coats, and then aliquots were frozen in cryopreservation medium (Cryostor CS10, Sigma), with the remainder freshly cultured. Frozen aliquots were thawed after a few days and cultured as before.

[0093] For therapeutic applications, freezing aliquots of monocytes to generate multiple macrophage doses is attractive. We assessed whether there were significant differences in macrophage yield or phenotype that would preclude the use of frozen stocks. The data indicated differences in both yield and phenotype. In particular, there was a significant decrease in CD206 and CD163 expression (Figure 2). There was also an inverse increase in CCR2 expression (Figure 2). This suggests that macrophages from frozen monocytes develop a classically activated phenotype, more similar to M1. Furthermore, in these experiments, the mean viability of macrophages from thawed monocytes was significantly lower than that of fresh monocytes (45.5% viability vs. 75.2% for fresh macrophages, n = 4–6, P = 0.0098). It was concluded that the low viability (and therefore yield) and less favorable phenotype preclude further development of macrophage products from frozen cells for early clinical use.

[0094] Example 2 Diastolic function analysis: healthy donor macrophages Phagocytic uptake by monocytes and macrophages Functional characterization of normal macrophages investigated the cells' ability to ingest particles. Using pHRodo beads, which only fluoresce when ingested into acidic endosomes, we tested both monocytes and macrophages from buffy coat CD14 cells for phagocytic uptake. Briefly, monocytes or macrophages were incubated with 1–2 μL of pHRodo E. coli bioparticles (Life Technologies, Thermo Fisher Scientific) for 1 hour, after which the medium was removed and the cells were washed to remove non-phagocytosed particles. Phagocytosis was assessed using an EVOS microscope (Thermo Fisher Scientific), images were acquired, and cellular uptake of the beads was quantified using ImageJ software (NIH freeware, https: / / imagej.nih.gov / ij). The use of pHRodo beads in these studies provides an accurate assessment, as the beads are transparent until engulfed and exposed to the acidic environment of the phagolysosome, where they fluoresce. Phagocytosis was quantified from EVOS images (Figure 3A) to assess the total number of cells per field, the total number of cells containing fluorescent beads, and the number of beads per cell. Quantification of phagocytosis using this method demonstrated no difference between monocyte and macrophage uptake (Figure 3B). Further analysis showed that stimulation of macrophages with TNF-α and poly I:C had no significant effect on phagocytosis (data not shown).

[0095] Macrophage polarization at the time of harvest Phenotypic analysis showed that macrophages at harvest were not polarized, but they demonstrated high CD206 and CD169 expression, characteristic of alternatively activated macrophages (Figure 6). IFN-γ and IL-4 stimulation were used to determine whether macrophages at harvest were capable of responding to polarizing cytokine exposure. Their ability to polarize into defined differentiated macrophages was investigated by treating day 7 macrophages with interferon (IFN)-γ (50 ng / mL) or interleukin (IL)-4 (20 ng / mL) for 48 hours to induce polarization toward an M1 or M2 phenotype (or M[IFNγ] vs. M[IL-4], respectively). After 48 hours, cells were visualized with an EVOS brightfield microscope, harvested, and phenotyped as before. At day 2 of polarization, there were morphological differences between the cultures; IFN-γ-treated macrophages exhibited a curved, angular shape (Figure 4A), while IL-4-treated macrophages displayed a characteristic spindle-shaped morphology. Although there was no significant difference in 25F9 marker expression between the cultures, IL-4-treated cells were able to significantly upregulate CD206, which is characteristic of polarized M2a macrophages (Figure 4B). This polarization is characteristic of macrophages in vitro and does not necessarily predict functional capacity in the recipient.

[0096] Macrophage cytokine and growth factor secretion profile The final aspect of cell product evaluation was the determination of macrophage factor secretion profiles at rest and after stimulation (Figure 5). Macrophages were generated from healthy donor buffy coats as before and either left untreated or stimulated with tumor necrosis factor (TNF)-α (50 ng / mL, Peprotech) and polyinosinic:polycytidylic acid (Poly I:C, a viral homolog that binds to TLR3, 1 μg / mL, Sigma) to mimic the conditions present in inflamed livers, or with lipopolysaccharide (LPS, 100 ng / mL, Sigma) and IFN-γ (50 IU / mL, Peprotech) to generate maximal macrophage activation. Day 7 macrophages were incubated overnight, and the supernatant was collected, centrifuged to remove debris, and stored at -80°C until testing. Secretome analysis was performed using a 27-plex human cytokine kit and a 9-plex matrix metalloproteinase kit on an aMagpix multiplex enzyme-linked immunoassay plate reader (BioRad). Resting macrophages expressed low levels of IL-1Ra, IL-10, and vascular endothelial growth factor (VEGF). To mimic an inflammatory environment, stimulation with TNF-α and poly I:C significantly increased the production of the pro-regenerative / anti-inflammatory factors VEGF, IL-10, and IL-1Ra, but not IL-12. LPS / IFN-γ stimulation did not significantly increase IL-10 expression, whereas LPS / IFN-γ strongly increased IL-12 expression. TNF-α / poly I:C stimulation significantly increased the expression of CCL3, CCL4, and CCL5, but not CCL2. Macrophages constitutively expressed high levels of MMPs 7, 9, and 12, and low expression of MMP 3. This MMP expression was not significantly regulated after stimulation or polarization, and expression of MMPs 1, 7, 8, 10, and 11 was negligible (data not shown).

[0097] Example 3 Process verification for patients with liver cirrhosis Culturing monocytes from patient samples

[0098] Monocytes cultured from leukapheresis from Prodigy isolation were cultured in 1 cm culture bags (MACS GMP differentiation bags, Miltenyi) with GMP-grade TexMACS (Miltenyi) and 100 ng / mL M-CSF. 2 and 2 x 10 per mL 6 Monocytes were cultured with 100 ng / mL GMP-compliant recombinant human M-CSF (R&D Systems). Cells were cultured at 37°C in a humidified atmosphere with 5% CO2 for 7 days. During culture, 50% of the culture medium was removed (to restore the final concentration to 100 ng / mL) and replaced with fresh medium supplemented with 200 ng / mL M-CSF (50% volume supplement) twice (days 2 and 4).

[0099] Process Validation Cell culture and differentiation data were used to design and validate the GMP process. A set of markers was selected from a broad phenotypic panel for use as product release criteria, including cell differentiation and functional markers. These were expression of CD45 and CD14 for lineage commitment and expression of 25F9 as a marker of macrophage maturity. Additionally, CD206 was selected as a surrogate marker of phagocytosis and clearance capacity, effectively identifying the development of appropriate functional macrophages. The viability stain DRAQ7 was included as the final component of the GMP release criteria panel. For further information on the cell product, a second phenotypic set, referred to as the extended panel, was used, assessing expression of CD163, CD169, and CCR2. This panel was validated on leukapheresis donations from seven cirrhotic volunteers.

[0100] The expression of cell surface markers for monocytes and macrophages was analyzed using either a FACSCanto II (BD Biosciences) or a MACSQuant 10 (Miltenyi) flow cytometer. Approximately 20,000 events were acquired for each sample. Cell surface expression of leukocyte markers in freshly isolated and day 7 mature cells was determined by incubating the cells with specific antibodies (final dilution 1:100). Cells were incubated with FcR block (Miltenyi) for 5 minutes, followed by incubation with the antibody cocktail for 20 minutes at 4°C. Cells were washed with PEA and the dead cell exclusion dye DRAQ7 (BioLegend) was added at 1:100. Cells were stained with various surface markers: CD45-VioBlue, CD14-PE or CD14-PerCPVio700, CD163-FITC, CD169-PE, and CD16-APC (all Miltenyi), CCR2-BV421, CD206-FITC, CXCR4-PE, and CD115-APC (all BioLegend), and 25F9-APC and CD115-APC (eBioscience). Both monocytes and macrophages were gated to exclude debris, doublets, and dead cells using forward and side scatter and a DRAQ7 dead cell discriminator (BioLegend), and analyzed using FlowJo software (Tree Star). From the initial detailed phenotyping, a panel was developed as the release criteria (CD45-VB / CD206-FITC / CD14-PE / 25F9-APC / DRAQ7) that defined the development of functional macrophages from monocytes. Macrophages were determined to have a mean fluorescence intensity (MFI) for both 25F9 and CD206 that was 5-fold higher than the levels of monocytes on day 0. A second panel was developed to evaluate other markers as part of an expanded panel, consisting of CCR2-BV421 / CD163-FITC / CD169-PE / CD14-PerCP-Vio700 / CD16-APC / DRAQ7, but was not used as part of the cell product release criteria.

[0101] CD14+ cells were selected using the CliniMACS Prodigy device and cultured as described above. The expression levels of each marker are shown in Figure 6 for enriched monocytes on day 0 and corresponding macrophages on day 7. Differentiated cells retained CD45+ CD14+ expression, while 25F9, CD206, CD169, and CD163 were significantly elevated in macrophages. Compared to monocytes, CCR2 became significantly downregulated in macrophages. The migratory capacity of macrophages after collection was also assessed using a transwell chemotaxis assay, confirming that they retained the ability to migrate to appropriate targets in vitro despite CCR2 downregulation (data not shown).

[0102] Stability of monocytes after collection from patients with liver cirrhosis Stability studies were performed on macrophages stored at controlled room temperature (21–22 °C) in the optimal excipient (clinical-grade 0.9% saline with 0.5% HAS) determined during process optimization. Various excipients were tested during process development, including PBS / EDTA buffer (0.5% HAS (Alburex), 0.9% saline alone, or PBS / EDTA buffer with saline containing 0.5% HAS). 0.9% saline with 0.5% HAS excipient (Baxter) was found to maintain optimal cell viability and phenotype (data not shown). The stability of macrophages from cirrhotic donors after collection was investigated in three process optimization runs, and a more limited range of time points was evaluated in a process validation run (n = 3). After harvest and resuspension in vehicle (0.9% saline for injection, 0.5% human serum albumin), the bags were stored at room temperature (21-22°C) and samples were taken at 0, 2, 4, 6, 8, 12, 24, 30, and 48 hours after harvest. A release benchmark antibody panel was run on each sample, and viability and mean fold change from day 0 were measured from the geometric MFI of 25F9 and CD206. After sampling at each time point, cells were assessed for phenotype and viability. Data from all three process optimization runs were analyzed for cell viability and phenotype (25F9 / CD206). Both the MFI and CD206 MFI were maintained for 48 hours after harvest (Figure 7), demonstrating that the process reproducibly produces a highly stable cell product. Therefore, release criteria were established that macrophages must be CD45 / CD14 positive, have a viability greater than 80%, and have MFIs for 25F9 and CD206 greater than 5-fold higher than the MFI of the original monocytes on day 0. All final results of the release criteria process validation, including stability, are listed in Table 1.

[0103] [Table 1]

[0104] Particulars include the parameters used as release criteria for the final product.

[0105] Example 4 Autologous monocyte-derived macrophage therapy for human trials A. Single Ascending Dose (SAD) Phase I Clinical Trial Patient recruitment Eligibility criteria were an age range of 18 to 75 years, a MELD range of 10.00 to 16, and cirrhosis defined as any of the following: alcohol-related liver disease (ALD), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), cryptogenic cirrhosis, hemochromocytosis, α-1-antitrypsin deficiency, or treated (sustained viral response) hepatitis C. Exclusion criteria included portal hypertensive bleeding in the past 3 months, ascites not adequately controlled with diuretic therapy in the past 3 months, encephalopathy requiring hospitalization for treatment in the past 3 months, hepatocellular carcinoma (excluding hypoplastic or indeterminate nodules, including regenerative or other nodules), a previous diagnosis of hepatocellular carcinoma, and previous organ transplant or tissue recipient. Other exclusion criteria included: alcohol or drug abuse, residence far from the study site, non-compliance or lack of cooperation, clinically relevant acute illness that would interfere with study participation, presence or history of cancer within the past 5 years, and pregnancy or breastfeeding.

[0106] [Table 2A]

[0107] [Table 2B]

[0108] Autologous non-polarized macrophage products CD14+ monocytes are isolated from the leukapheresis product using the CliniMACS Prodigy® closed system. As described above, CD14+ monocytes are cultured in low-adherence culture bags (Miltenyi) in the presence of TexMACS™ serum-free medium (Miltenyi) and 100 ng / ml M-CSF (R&D Systems) for 7 days. 33% medium changes are performed on days 3 and 5. Furthermore, the final product is assessed for macrophage phenotypic markers (25F9 and CD14) and functional markers (CD206). Viability is assessed by DRAQ7 staining as described above. The final product is collected and cultured at a concentration of ≤1 x 10 cells in 125 mL of 0.9% saline (Baxter) and 0.5% human albumin solution. 7 ;≦1x10 8 or ≦1x10 9 The cells are prepared as a mass for infusion and the product is placed in a transfer bag (Terumo 150 mL transfer bag), overwrapped, and shipped to the investigator's site for use within 48 hours.

[0109] research design The first phase of the study will be designed as a standard 3+3 design to test cell safety and tolerability in humans. Autologous macrophages will be administered in one injection with three different cell doses: 10 7 , 10 8 , 10 9 Participants will receive the cells in a dose-escalating regimen using a pharmacokinetic (pharmacokinetic) assay. Each dose of cells will be administered to three participants. After macrophages differentiate from monocytes on day 7 after apheresis, participants will return to the clinical research unit. Prior to receiving the autologous macrophage product, participants will receive a 30-minute infusion of 10 mg IV chlorphenamine, 100 mg IV hydrocortisone, and 250 ml of normal saline via an intravenous cannula. The macrophage product will be administered intravenously over 30 minutes, followed by a 250 ml saline infusion over 15-20 minutes. Blood tests will be performed on participants 7 and 14 days after the infusion, and then at 30, 60, 90, 180, and 360 days.

[0110] Regenerating macrophages in patients with liver cirrhosis It has been demonstrated that regenerative macrophages can be derived from patients with liver cirrhosis. There were no significant differences in the gene expression of several markers, including CCL2, MMP9, IL10, and CCL3, in ex vivo differentiated macrophages from healthy and cirrhotic patients (Figure 8).

[0111] In the MATCH trial, MELD was measured at various time points. The first measurement was taken 3 to 6 months before the initial screening. This data point is called d-120, but each patient's actual blood tests were taken at different time points within the 3- to 6-month period. MELD was measured at the initial screening, i.e., baseline (d-14), and then at d7, d14, d30, d60, d90, d180, and d360. d0 is the day of administration of macrophage products.

[0112] MELD consists of three components; bilirubin (BIL), creatinine (CRE), and international normalized ratio (INR), which are combined using the following formula to generate the MELD score:

[0113] MELD=10*[(0.957*In(CRE(mmol / l)*0.011312217))+(0.378*In(BIL(mmol / l)*0.058479532))+(1.12*In(INR))]+6.43 (Huo et al., Journal of hepatology 2005; 42(6):826-32).

[0114] None of the MELD components can have a negative contribution, and the MELD score is rounded to the nearest integer. Table 3 shows the MELD data for all subjects in the MATCH trial. ΔMELD for all patients was calculated relative to baseline (day-14), with negative values ​​indicating an improvement in clinical status. Figure 9 shows the mean ΔMELD for all patients. The most significant response was observed from S05, where a transient decrease in MELD of 6 points was observed. Macrophage therapy is thought to be more effective in patients with cirrhosis whose underlying etiology is caused by hepatocytes. Because patient S04's etiology was primary biliary cholangitis (PBC), which is not thought to be caused by hepatocytes, it is not surprising that this patient showed a poor response to treatment.

[0115] To understand the mechanistic contribution of nonpolarized macrophage therapy to ΔMELD, the contribution of each component of MELD to ΔMELD was assessed and illustrated as shown in Figure 10. Results suggest that MELD scores decrease in two of the three components; BIL and INR, which account for 62% of the variance in ΔMELD, were explained by the contribution of BIL and the remainder from INR. No significant changes in MELD scores were observed for the contribution of the CRE component. These results suggest that the observed improvement in MELD is due to a direct improvement in liver function. Bilirubin is a byproduct of hemoglobin metabolism as a result of red blood cell death. Circulating bilirubin is glucuronidated by hepatocytes and then excreted via the bile duct. Therefore, BIL is a measure of hepatocyte health and function. INR, which is a result of the liver's ability to synthesize vitamin K-derived clotting factors, is a less direct measure of hepatocellular function than BIL, but also suggests improved liver health. In contrast, CRE is a renal marker and a surrogate for multiple organ failure associated with cirrhosis. Thus, our data demonstrate that nonpolarizing therapy not only has a beneficial effect on MELD, but that this effect is mediated by improved liver function, consistent with the proposed mechanism of action of the treatment.

[0116] [Table 3A]

[0117] [Table 3B]

[0118] Additionally, in the MATCH study, enhanced liver fibrosis (ELF), which provides a noninvasive measure of fibrosis, was measured at various time points, including screening (d-14), d30, d60, d90, d180, and d360. d0 is the day of macrophage product administration. Figure 11 shows the ELF scores for all patients in the MATCH study, Figure 12 shows the ΔELF for all patients in the MATCH study, and Figures 13, 14, and 5 show the analysis of each component of the ELF score—HA, PNIIIP, and TIMP1, respectively. The graphs show the overall reduction in enhanced liver fibrosis over the 360-day period measured.

[0119] The precisely cleaved N-terminal propeptide of type III collagen (PRO-C3) and peptides of helical collagen type III degradation (C3M) were measured at various time points including screening, screening (d-14), d30, and d90.

[0120] [Table 4]

[0121] The PRO-C3 data show a reduction in fibrosis formation.

[0122] [Table 5]

[0123] B. Phase II Trials A randomized controlled trial will be conducted. 28 participants will be randomized to receive standard medical care. The 28 participants will receive 10 mg of standard medical care at 30-day intervals. 9Receive a total of three injections of macrophages.

[0124] Autologous non-polarized macrophage products Monocytes cultured from leukapheresis from Prodigy isolation were cultured in 1 cm culture bags (MACS GMP differentiation bags, Miltenyi) with GMP-grade TexMACS (Miltenyi) and 100 ng / mL M-CSF. 2 and 2 x 10 per mL 6 Monocytes were cultured with 100 ng / mL GMP-compliant recombinant human M-CSF (R&D Systems). Cells were cultured at 37°C in a humidified atmosphere with 5% CO for 7 days. During culture (day 4), a single 50% volume medium feed was performed in which 50% of the culture medium was removed and fresh medium supplemented with 200 ng / mL M-CSF (to return to a final concentration of 100 ng / mL) was provided. Advantageously, this single feed (compared to two feeds) reduces cell manipulation and handling steps, resulting in reduced costs and reduced cell loss.

[0125] As described above, CD14+ monocytes are isolated from the leukapheresis product and characterized before being sent to the investigator's site.

[0126] Measurement results: Injected patients will have their outcomes assessed by one or more of the following assessments / measurements: MELD and Delta MELD; UKELD and Delta UKELD; Transient Elastography (Fibroscan™, Echosens, France) (Fraquelli et al., Gut, 2007; 56(7):968-73) - a non-invasive method for assessing liver fibrosis at screening, 90 days, 180 days, and 360 days; Enhanced Liver Fibrosis (ELF) test - ELISA assays for matrix components and enzymes involved in their turnover (hyaluronic acid, tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), procollagen type III (PIIINP)) with calculated ELF score for the level of liver fibrosis; 31-P-MRS and liver MRI scans: a non-invasive and quantitative measurement of liver metabolic and regenerative activity at random and 90 days after treatment; MRI of liver volume and blood flow. Other methods of assessing outcome include the CLDQ (Chronic Liver Disease Questionnaire) (Younossi et al., Gut 1999; 45(2); 295-300) and those described by Newsome et al., Gastroenterol Hepatol. 2018; 3:25-36.

[0127] Additional analyses may include measuring changes in protein markers: During extracellular matrix (ECM) turnover, proteolytically cleaved matrix degradation fragments, or neoepitopes, are released into the systemic circulation. Cleavage of each ECM protein by specific MMPs generates unique neoepitopes. These neoepitopes may be more accurate diagnostic and prognostic markers for an individual's fibroproliferative disease than their original proteins. A method for detecting these specific protein fragments to identify and quantify disease is Protein Fingerprint™ technology (Nordic Bioscience). These novel serum biomarkers have been shown to identify patients with advanced fibrosis, enable monitoring of response to antifibrotic therapy, and correlate with portal hypertension in patients with cirrhosis.

[0128] [References] TIFF0007581049000008.tif217168TIFF0007581049000009.tif238168TIFF0007581049000010.tif195168TIFF0007581049000011.tif133168

Claims

1. A composition for use in a method of treating fibrosis in a human in need thereof, the composition comprising non-polarized macrophages characterized by elevated expression of 25F9 and / or CD206 compared to expression of these markers in source macrophage precursor or progenitor cells, wherein the human in need thereof has a sclerosing liver disease.

2. The composition of claim 1 for treating fibrosis by administering one or more doses of said non-polarized macrophages to a human in need thereof.

3. The composition of claim 1 or 2, wherein the non-polarized macrophages are derived from the human's own PBMCs or stem cells, including bone marrow, embryonic stem cells or induced pluripotent stem cells.

4. 3. The composition of claim 2, wherein the one or more doses are administered at intervals of approximately 30 days, and the non-polarized macrophages are derived from the human's own PBMCs, or stem cells, including bone marrow, embryonic stem cells, or induced pluripotent stem cells.

5. The composition of any one of claims 1 to 4, wherein the human in need thereof is an affected patient with a MELD score of 10 to 16.

6. 1. A composition for use in a method of treating liver fibrosis by administering three doses to a human in need thereof, a first dose being administered on day 1, a second dose on day 30, and a third dose on day 60, the composition comprising non-polarized macrophages characterized by elevated expression of 25F9 and / or CD206 compared to expression of these markers in source macrophage progenitor or precursor cells.

7. 7. A composition according to any one of claims 1 to 6 for use by intravenous administration.

8. 1×10 7 From 1×10 98. A composition according to any one of claims 1 to 7, for use by administration of one or more doses comprising macrophages of said 9. The composition of claim 5, wherein the cirrhotic liver disease is caused by high alcohol consumption, obesity, metabolic disorders, or viral infection, most preferably alcohol-induced cirrhosis, NASH or HCV.

10. The composition of any one of claims 1 to 9, wherein the macrophages are of monocyte origin.

11. 11. The composition of any one of claims 1 to 10, wherein the macrophages are characterized by elevated expression of the surface markers 25F9 and CD206 that is at least 5-fold compared to the expression of one or both of these markers in source macrophage progenitor or precursor cells.

12. The composition of any one of claims 1 to 11, wherein the macrophages are further characterized by increased expression of one or more of CD163 and CD169.